DOCSLIB.ORG

Monitoring of Streptokinase Resistance Titre in Acute Myocardial Infarction

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Monitoring of Streptokinase Resistance Titre in Acute Myocardial Infarction Br Heart J 1992;68:167-70 167 Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG R Fears, H Ferres, E Glasgow, R Standring, K J Hogg, J D Gemmill, J M A Burns, A P Rae, F G Dunn, W S Hillis Abstract Varying concentrations of antibodies to strep- Objective-To examine the induction tokinase (SK) may be present in patients with of antistreptokinase antibodies after acute myocardial infarction (AMI) as a result giving streptokinase or anistreplase to of previous streptococcal infections."2 The patients with acute myocardial infarc- induction of anti-streptokinase (anti-SK) tion. antibodies after the administration of SK or Design-Patients were randomly anistreplase (Eminase, APSAC) is, therefore, allocated to receive either 15 x 10' IU, an anamnestic response. Previous studies on streptokinase or 30U anistreplase in a SK have measured the antibody response with double blind study. Blood samples were a surrogate endpoint, the functional SK resis- collected immediately before treatment tance titre, which also reflects the influence of and subsequently at intervals up to 30 inhibitors such as a2 antiplasmin and varia- months; plasma samples were assayed tions in other plasma proteins such as fibrin- for streptokinase resistance titre (func- ogen and plasminogen."35 These studies have tional assay) and streptokinase binding shown that a peak value was reached by two by IgG (microradioimmunoassay). weeks after dosing with SK and returned Setting-Cardiology department in a towards pretreatment values by six months. general hospital. The development of neutralising antibodies Patients-128 consecutive eligible may influence the efficacy and risk of an patients. Samples were collected for up adverse reaction to SK or anistreplase on to one year according to a prospective readministration for a subsequent myocardial design: a subsection of 47 patients was infarction, and in the context of the increasing selected for intensive study over the first use of thrombolytic therapy this might 14 days. After one year, all available become an increasingly relevant clinical patients (67) were sampled on one fur- problem. It is therefore important to define the ther occasion. times of induction and decline in a population Results-Antibody responses to strep- large enough to reflect the range of individual tokinase and anistreplase were similar. variations in neutralising antibody concentra- Streptokinase resistance titres exceeded tion. It was the purpose of the present work to pretreatment concentrations five days compare changes in SK resistance titre in after dosing, and values peaked at 14 response to the standard doses of SK and 12 months of SmithKline Beecham days. By after dosing, 92% anistreplase in patients with AMI. The results Pharmaceuticals, resistance titres (n = 84) had returned to from this functional assay were compared Great Burgh, Epsom, within the pretreatment range. Anti- with those from a novel method of assaying Surrey streptokinase concentrations also one class in terms of R Fears IgG antibody (IgG) antigen H Ferres exceeded baseline concentrations within binding.6 E Glasgow five days and peaked at 14 days. Half of R Standring the individual values had returned to University within the pretreatment range by 12 Department of months (n = 84) and 89% 30 months Medicine and by Patients and methods = Therapeutics, Stobhill (n 18). PATIENTS General Hospital, Conclusion-Although we cannot be One Glasgow sure of the clinical significance, because hundred and twenty eight consecutive K J Hogg of the increased likelihood of resistance eligible patients (101 men, 27 women age range J D Gemmill 31-70) were recruited between April 1987 and J M A Burns due to antistreptokinase antibody, strep- 1989. Inclusion and A P Rae tokinase and anistreplase may not be January exclusion criteria F G Dunn if more five and adjunct treatments have been described W S Hillis effective administered than previously.7 Patients were randomised in days after an earlier dose of streptokin- Correspondence to: double blind, double dummy fashion to receive Dr R Fears, SmithKline ase or anistreplase, particularly between either 1-5 x 106IU SK infused Beecham Pharmaceuticals, five days and 12 months, and increased intravenously Great Burgh, Yew Tree over one hour or 30 U anistreplase injected Bottom Road, Epsom, antistreptokinase antibody may increase intravenously overfiveminutes. Initial patency, Surrey KT18 5XQ the risk of allergic-type reactions. Accepted for publication rates of reocclusion, and adverse events are 13 January 1992 (Br Heart J 1992;68: 167-70) described elsewhere.7 168 Fears, Ferres, Glasgow, Standring, Hogg, Gemmill, Burns, Rae, Dunn, Hillis Evaluation ofvariations in streptokinase resistance titre after dosing with streptokinase or anistreplase Period offollow up (months with range) Analysis 3 6 12 (11-15) 18 (16-20) 24 (21-27) 30 (28-31) Median evaluation as fold increase over 20 (39)t 15 (38) 4 (60) 5 (22) 2 (20) 2 (18) individual pretreatment value (n) Values (%) returning to: Within pretreatment range 51 72 92 100 100 100 Within 95th percentile pretreatment range 31 44 76 86 77 88 For all patients (n) (45)t (50) (84) (22) (26) (18) Theoretical neutralisation of streptokinase (IU) (combininggroupmedian)* 1-2 x 106 12 x 106 6 x 105 3 x 105 3 x 105 3 x 105 *Theoretical neutralisation by pretreatment median value = 1 5 x IO' (assuming a standard plasma volume of 31). tNumbers of patients in the two types of analysis differ because median evaluation could only be calculated for those patients for whom pre and post treatment pairs of samples were available. At any one sampling time these pairs of samples are fewer than the total number of patients sampled. Blood samples were collected from patients are normally distributed, and the conclusions before dosing and serially at intervals for up to are similar to those derived from a considera- one year in a prospectively designed study. A tion of median values. The SK resistance and subsection of 47 patients was selected for antiSK IgG results were analysed by the intensive study over the first 14 days although Mann-Whitney U test. not all samples were received from each patient. Figures 1 and 3 show data from this cohort. The remaining figures and tables show Results available data for all patients. After one year all SK RESISTANCE TITRE available patients (67) were sampled on one Early serial changes (one to 14 days) were further occasion and these patients were studied in detail in a subgroup of 47 patients. grouped according to the classification de- The response was similar whether patients scribed in the table. were treated with SK or anistreplase, and baseline (pretreatment) values were consis- LABORATORY ASSESSMENTS tently exceeded by five days after dosing (fig 1). The SK resistance titre and antiSK IgG con- Figure 2 shows results for all patients, centrations were measured in individual monitored up to 30 months. Measurements up plasma samples as described previously.6 Cal- to 12 months are serial analyses in the same culations of the theoretical neutralisation of a patients (although a maximum ofonly 84 out of second dose of SK were performed by multi- a possible 115 samples were collected in the plying the SK resistance titre by the average prospectively designed study). By contrast, plasma volume of 3 litres. each patient was only sampled once over the period 12-30 months; that is, different patients STATISTICAL ANALYSIS appear in the groups collated at 18, 24, and 30 The SK resistance titres and anti-SK IgG months and therefore groups are smaller at concentrations, as analysed by either the Wilk- these times. Sampling times for the points Shapiro or the Kolmogorov-Smirnov test, within the period 12-30 months represent were not normally distributed and so cannot be ranges: the total ranges are specified in the table. represented as arithmetic means. Values for Changes in SK resistance titre were similar SK resistance titres and for comparison IgG for SK and anistreplase throughout the period are shown as median values with ranges. The of follow up (fig 2). Baseline (pretreatment) IgG values have also been analysed as values however were significantly higher in the geometric means as the log transformed values group of patients assigned to treatment with anistreplase (50 v 20 IU/ml, p < 0 05). Peak titres were reached two weeks after Figure 1 Initial changes in SK resistance titre. 'a Values are shown as E median and range for en -~10000 patients who received SK Q (open bars) or anistreplase m (stippled bars). Patient numbers are indicated (n). 0 CL Das 0 :, (D Oh 7 14 1 2 3 6 12 18 24 30 1n in - n v-cv cn o a coo am c a) r- ONc Days Months C4 _-_N- -C C C_d4- 4 N _ _ Oh 1 2 3 4 5 6 7 14 Sampling time Days Figure 2 Changes in SK resistance titre up to 30 Sampling time months. See legend tofig 1 for details. Monitoring ofstreptokinase resistance titre in acute myocardial infarction patients 169 Figure 3 Initial changes in anti-SK IgG. See early fall in IgG (fig 3) is not accompanied by a legend tofig 1 for details. E similar decline in SK resistance titre (fig 1). n Figure 4 showed results for all patients Q monitored to a up 30 months: changes in anti- SK IgG were similar for SK and anistreplase 01 throughout the period of follow up. It is ._ noteworthy that baseline values are not higher in the patients assigned to anistreplase, unlike cn the situation with SK resistance titre (fig 2). -0 01 In agreement with the changes in SK resis- cn tance titre, peak values of anti-SK IgG were attained 14 days after dosing (150 fold rise in median).
Load more

Recommended publications
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Malik2018.Pdf
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Nat Genet Manuscript Author . Author manuscript; Manuscript Author available in PMC 2018 May 25. Published in final edited form as: Nat Genet. 2018 April ; 50(4): 524–537. doi:10.1038/s41588-018-0058-3. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes A full list of authors and affiliations appears at the end of the article. Abstract Stroke has multiple etiologies, but the underlying genes and pathways are largely unknown. We conducted a multiancestry genome-wide-association meta-analysis in 521,612 individuals (67,162 cases and 454,450 controls) and discovered 22 new stroke risk loci, bringing the total to 32. We further found shared genetic variation with related vascular traits, including blood pressure, cardiac traits, and venous thromboembolism, at individual loci (n = 18), and using genetic risk scores and linkage-disequilibrium-score regression. Several loci exhibited distinct association and pleiotropy patterns for etiological stroke subtypes. Eleven new susceptibility loci indicate mechanisms not previously implicated in stroke pathophysiology, with prioritization of risk variants and genes accomplished through bioinformatics analyses using extensive functional datasets. Stroke risk loci were significantly enriched in drug targets for antithrombotic therapy. Stroke is the second leading cause of death and disability-adjusted life years worldwide1,2. Characterized by a neurological deficit of sudden onset, stroke is primarily caused by brain infarction (ischemic stroke) and, less often, by intracerebral hemorrhage (ICH). Common etiological subtypes of ischemic stroke include large-artery atherosclerotic stroke (LAS), cardioembolic stroke (CES), and stroke caused by small-vessel disease (small-vessel stroke (SVS)), which is also the leading cause of ICH.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Antithrombotic Agents in the Management of Sepsis
    Antithrombotic Agents in the Management of Sepsis !"#$ Loyola University Medical Center, Maywood, Illinois-60153, USA ABSTRACT Sepsis, a systemic inflammatory syndrome, is a response to infection and when associated with mul- tiple organ dysfunction is termed, severe sepsis. It remains a leading cause of mortality in the critically ill. The response to the invading bacteria may be considered as a balance between proinflammatory and antiinflammatory reaction. While an inadequate proinflammatory reaction and a strong antiinflammatory response could lead to overwhelming infection and death of the patient, a strong and uncontrolled pro- inflammatory response, manifested by the release of proinflammatory mediators may lead to microvas- cular thrombosis and multiple organ failure. Endotoxin triggers sepsis by releasing various mediators inc- luding tumor necrosis factor-alpha and interleukin-1(IL-1). These cytokines activate the complement and coagulation systems, release adhesion molecules, prostaglandins, leukotrienes, reactive oxygen speci- es and nitric oxide (NO). Other mediators involved in the sepsis syndrome include IL-1, IL-6 and IL-8; arachidonic acid metabolites; platelet activating factor (PAF); histamine; bradykinin; angiotensin; comp- lement components and vasoactive intestinal peptide. These proinflammatory responses are counterac- ted by IL-10. Most of the trials targeting the different mediators of proinflammatory response have failed due a lack of correct definition of sepsis. Understanding the exact pathophysiology of the disease will enable better treatment options. Targeting the coagulation system with various anticoagulant agents inc- luding antithrombin, activated protein C (APC), tissue factor pathway inhibitor (TFPI) is a rational appro- ach. Many clinical trials have been conducted to evaluate these agents in severe sepsis.
    [Show full text]
  • Cloning, Expression, and Renaturation Studies of Reteplase
    J. Microbiol. Biotechnol. (2003), 13(6), 989–992 Cloning, Expression, and Renaturation Studies of Reteplase 1 1,2 1 1 ZHAO, YOUCHUN , WANG GE , YANG KONG , AND CHANGKAI ZHANG 1State Key Laboratory of Microbial Technology, Shandong University, Jinan 250100, P.R. China 2Shandong Younglong Biotechnology Co., Jinan 250100, P.R. China Received: September 9, 2002 Accepted: July 4, 2003 Abstract Recombinant human tissue plasminogen activator deletion mutein (Reteplase, abbreviated as r-PA) represent deletion mutein (Reteplase) is a clinically promising thrombolytic one of the third generation thrombolytic drugs. Reteplase drug. Reteplase cDNA was subcloned into a bacteria expression manifests advantages in large-scale production, prolonged system, and the resultant recombinant was biologically half-time, thromobolytic potency, and fewer side effects, characterized. The Reteplase was expressed in Escherichia thus it attracts great attention from cardiovascular experts coli as an inclusion body, and the downstream processes of the [6, 16]. Reteplase inclusion body included denaturation, renaturation, Reteplase has been obtained by deleting the three and purification. A protein disulfide isomerase (PDI) was used structural domains of Kringle I, Finger, and EGF, while to assist the refolding of Reteplase, and it was found to increase retaining the thrombolytic Kringle II, protease domain, the refolding rate from less than 2% to more than 20%. The two functional regions of protease (amino acid residues refolded Reteplase was purified through two chromatography 176- 527), as well as the N-terminal 1 to 3 amino acid steps, including lysine-coupled agarose affinity chromatography residues [8, 10, 12, 17]. Reteplase expressed in Escherichia and then CM-sepharose cation-exchange chomatography.
    [Show full text]
  • Appendix C Medication Tables
    Appendix C Medication Tables Note: The medication tables are not meant to be inclusive lists of all available therapeutic agents. Approved medication tables will be updated regularly. Discrepancies must be reported. See Resource Section of this manual for additional contact information. Release Notes: Aspirin Table Version 1.0 Table 1.1 Aspirin and Aspirin-Containing Medications Acetylsalicylic Acid Acuprin 81 Alka-Seltzer Alka-Seltzer Morning Relief Anacin Arthritis Foundation Aspirin Arthritis Pain Ascriptin Arthritis Pain Formula ASA ASA Baby ASA Baby Chewable ASA Baby Coated ASA Bayer ASA Bayer Children's ASA Buffered ASA Children's ASA EC ASA Enteric Coated ASA/Maalox Ascriptin Aspergum Aspir-10 Aspir-Low Aspir-Lox Aspir-Mox Aspir-Trin Aspirbuf Aspircaf Aspirin Aspirin Baby Aspirin Bayer Aspirin Bayer Children's Aspirin Buffered Aspirin Child Aspirin Child Chewable Aspirin Children's Aspirin EC Aspirin Enteric Coated Specifications Manual for National Appendix C-1 Hospital Quality Measures Table 1.1 Aspirin and Aspirin-Containing Medications (continued) Aspirin Litecoat Aspirin Lo-Dose Aspirin Low Strength Aspirin Tri-Buffered Aspirin, Extended Release Aspirin/butalbital/caffeine Aspirin/caffeine Aspirin/pravachol Aspirin/pravastatin Aspirtab Bayer Aspirin Bayer Aspirin PM Extra Strength Bayer Children’s Bayer EC Bayer Enteric Coated Bayer Low Strength Bayer Plus Buffered ASA Buffered Aspirin Buffered Baby ASA Bufferin Bufferin Arthritis Strength Bufferin Extra Strength Buffex Cama Arthritis Reliever Child’s Aspirin Coated Aspirin
    [Show full text]
  • Drugs Affecting Coagulation
    PHARMACOLOGY Drugs affecting Learning objectives coagulation After reading this article, you should be able to: C outline the process of coagulation Balraj Appadu C compare and contrast the different drugs used for Katrina Barber anticoagulation C evaluate anticoagulant drugs and their uses in patients under- going surgery Abstract For more than half a century, heparin and vitamin K antagonists have defined anticoagulant therapy in both the short-term and long-term leading to dissolution (lysis) and restoration of blood flow to the management of thrombotic diseases. However, the limitations of organs. these traditional anticoagulants have prompted the development of new drugs. In the past 15 years new agents with improved safety pro- First-generation agents fi le and greater ease of use that target almost every step of the coag- Streptokinase is a non-enzymatic protein produced by b-hae- ulation cascade have been developed. These include factor Xa molytic streptococci. It activates the fibrinolytic system indi- inhibitors and direct thrombin inhibitors. The mechanism of action of rectly, binding to human plasminogen and forming a 1:1 ‘ ’ these new anticoagulants and also the older agents are reviewed in stoichiometric complex, which converts plasminogen into this article. plasmin. It is associated with allergic reactions and can stimulate Keywords ADP receptor antagonists; dabigatran; fondaparinux; the production of anti-streptococcal antibodies. For this reason, glycoprotein IIb/IIIa antagonists; heparin; rivaroxaban; warfarin repeat doses should be avoided. Urokinase is a trypsin-like serine protease composed of two Royal College of Anaesthetists CPD Matrix: A102 polypeptide chains connected by a disulphide bridge. It activates plasminogen directly, converting it to active plasmin.
    [Show full text]
  • Heparin TAP Report
    CFNP TAP Review Heparin 8/16/2002 HEPARIN Livestock Executive Summary Heparinic acid, or heparin, is highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but in humans it is used to prevent blood clotting in vivo and in vitro, in the form of many different salts. 1 The subject of the petition is a request for heparin to be approved for use in organic livestock medical treatment. Heparin is used in blood transfusions to prevent the donor’s blood from coagulating prior to administration, as well as in animals at risk of thrombosis due to endotoxemia and disseminated intravascular coagulopathy. Summary of TAP Reviewer Analyses 2 Synthetic/ Allow without restrictions? Allow only with restrictions? (See Reviewers’ Nonsynthetic comments for restrictions) Synthetic (3) Yes (1) No (2) No (2) Identification Chemical names: Heparin, Heparinic acid Other Names: Calcilean, Calciparine, Hepalean, Heparin Leo, Liquaemin Bemiparin, CY 216, CY 222, Certoparin, Clexane, Clivarin, Clivarine, Dalteparin, Enoxaparin, Eparina [DCIT], FR 860, Fluxum, Fragmin A, Fragmin B, Fraxiparin, Hed-heparin, Heparin CY 216, Heparin sulfate, Heparina [INN- Spanish], Heparinate, Heparine [INN-French], Heparinum [INN-Latin, Hepathrom, KB 101, Lipo-hepin, Liquemin, Multiparin, Novoheparin, OP 386, OP 622, Pabyrin, Parnaparin, Parvoparin, Pularin, Reviparin, Sandoparin, Sublingula, Thromboliquine, Vetren, Vitrum AB, alpha-Heparin, depo-Heparin CAS Number: #9005-49-6 Other numbers: EINECS #232-681-7 HSDB #3094 NIOSH: MI0700000 RTECS Number : MI0850000 1 “Heparin.” ChemID Plus. http://toxnet.nlm.nih.gov/cgi-bin/sis/search 2 This Technical Advisory Panel (TAP) review is based on the information available as of the date of this review.
    [Show full text]
  • Plasminogen-Streptokinase
    Drugs used in coagulation disorders 2019 Laszlo Köles [email protected] http://semmelweis.hu/pharmacology Basic principles of blood coagulation Normal (not damaged) vascular endothel - antithrombogenic Vascular injury initiates events leading to • vasospasm • platelet adhesion and aggregation - white thrombus • blood coagulation - red thrombus • fibrinolysis • cell proliferation, repair mechanisms Birth of a thrombus platelets tissue factor fibrin platelets + tissue factor platelets + fibrin platelets + fibrin + tissue factor Furie B, Furie BC. Thrombus formation in vivo. J Clin Invest. 2005 DRUGS USED IN THROMBOEMBOLIC DISORDERS • Antiplatelet drugs • Anticoagulants • Fibrinolytics Antiplatelet drugs Thrombocytes I. Circulating platelets at rest - small, discoid anuclear cells Vascular injury - platelet adhesion, activation, aggregation collagen-contact - adhesion of platelets to surface glycoprotein Ib/IX - vWF, fibronectin, vitronectin, thrombospondin activation release reaction (e.g. ADP, serotonin) pseudopods (higher surface) synthesis of thromboxan A2 Thrombocytes II. Activators of thrombocytes collagen-contact agonists of the G-protein coupled surface receptors thrombin (PAR-1 receptor) ADP (P2Y1 and P2Y12 receptors) serotonin (5-HT2A receptor) epinephrine (2 receptor) Role of eicosanoids: thromboxane A2 prostacycline Aggregation of platelets GP IIb/IIIa receptor - binding to fibrinogen and other RGD proteins (-Arg-Gly-Asp e.g. vWF, vitronectin) - bridges between thrombocytes Antiplatelet drugs Mechanisms of
    [Show full text]
  • Core/Quality Measures Reference Sheet 07-01-16 Through 12-01-16 Discharges
    Core/Quality Measures Reference Sheet 07-01-16 through 12-01-16 Discharges CMS Expanded Measure Sets STROKE STROKE (This addresses both primary stroke diagnoses as Fibrinolytic Agents well as strokes that occur during hospitalization, i.e. post-op) • VTE Prohylaxis Abbokinase APSAC Streptokinase • Antithrombotics at discharge Activase Eminase Tenecteplase • Anticoagulation at discharge for atrial fibrillation Alteplase Kabikinase Tissue plasminogen • IV tPA (arrival 2 hr, treat 3 hr) Anistreplase Retavase Activator Anisoylated Plasminogen- Reteplase TNKase • Antithrombotic end of Day 2 Streptokinase Activator rPA (RPA) tPA (TPA) • Lipids drawn, treat with Statin prescribed at Discharge Complex Streptase • Patient receives stroke education which include: - Personable modifiable risk factors for stroke Anticoagulant Medications - Stroke - How to activate EMS for stroke - Stroke warning S&S Argatroban Enoxaparin Lovenox - Their prescribed medications - Need for F/U after discharge Arixtra Fondaparinux Pradaxa • Assessed for Rehab Coumadin Fragmin Refludan • Dysphagia screen prior to PO intake Dabigatran Heparin I.V. Rivaroxaban Dabigatran etexilate Innohep Tinzaparin VTE Dalteparin Jantoven Warfarin VTE 5 (Applies to patients diagnosed with confirmed VTE Lepirudan Warfarin Sodium that are discharged home on warfarin with written discharge Xarelto instructions that address all 4 criteria.) 1. Discharge instructions Address Compliance Issues (Include Warfarin all): Coumadin Warfarin • Taking warfarin as instructed Jantoven Warfarin Sodium
    [Show full text]
  • Healthy U Medical Pharmacy Prior Authorization List
    Below is the list of Medical Drug J‐codes that require pre‐service review for Healthy U Medicaid. Please submit the Medical Utilization Management Review form (select Medical Pharmacy from the drop down), attach all necessary clinical documentation and submit to the U of U Health Plans Pharmacy Team by either fax to 801‐213‐1547 or by email: [email protected] If you have questions or need assistance please call for: 801‐213‐4104; Toll Free 833‐981‐0212 CODE DESCRIPTION PA Status Notes 0537T Chimeric antigen receptor T‐cell (CAR‐T) therapy; harvesting of blood‐derived T lymphocytes for Not Covered development of genetically modified autologous CAR‐T cells, per day 0538T Chimeric antigen receptor T‐cell (CAR‐T) therapy; preparation of blood‐derived T lymphocytes for Not Covered transportation (eg, cryopreservation, storage) 0539T Chimeric antigen receptor T‐cell (CAR‐T) therapy; receipt and preparation of CAR‐T cells for Not Covered administration 0540T Chimeric antigen receptor T‐cell (CAR‐T) therapy; CAR‐T cell administration, autologous Not Covered A9513 Lutetium lu 177, dotatate, therapeutic, 1 millicurie PA Required A9589 Instillation, Hexaminolevulinate Hydrochloride, 100 mg PA Required B4164 Parenteral nutrition solution: carbohydrates (dextrose), 50% or less (500 ml = 1 unit) ‐ home mix PA Required B4168 Parenteral nutrition solution; amino acid, 3.5%, (500 ml = 1 unit) ‐ home mix PA Required B4172 Parenteral nutrition solution; amino acid, 5.5% through 7%, (500 ml = 1 unit) ‐ home mix PA Required B4176 Parenteral
    [Show full text]
  • INCB 18424-258 Protocol Amendment 2 and Agree to Conduct the Study As Outlined
    Incyte Corporation Page 1 of 92 Protocol INCB 18424-258 Amendment 2 09 AUG 2013 Clinical Study Protocol INCB 18424-258 / NCT01348490 An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-Myelofibrosis and Post Polycythemia Vera- Myelofibrosis Who Have Platelet Counts of 50 × 109/L to 100 × 109/L Product: Ruxolitinib IND Number: 77,456 Phase of Study: 2 Sponsor: Incyte Corporation Route 141 & Henry Clay Road Building E336 Wilmington, DE 19880 US Date of Protocol: 29 MAR 2011 Date of Protocol Amendment 1: 17 AUG 2011 Date of Protocol Amendment 2: 09 AUG 2013 This study will be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and conducted in adherence to the study protocol, Good Clinical Practices as defined in Title 21 of the US Code of Federal Regulations Parts 50, 54 56, 312, and Part 11 as well as ICH GCP consolidated guidelines (E6) and applicable regulatory requirements. The information in this document is confidential. No part of this information may be duplicated, referenced, or transmitted in any form or by any means (electronic, mechanical, photocopy, recording, or otherwise) without the prior written consent of Incyte Corporation. CONFIDENTIAL Incyte Corporation Page 2 of 92 Protocol INCB 18424-258 Amendment 2 09 AUG 2013 INVESTIGATOR'S AGREEMENT I have received and read the Investigator’s Brochure for ruxolitinib. I have read the INCB 18424-258 Protocol Amendment 2 and agree to conduct the study as outlined. I agree to maintain the confidentiality of all information received or developed in connection with this protocol.
    [Show full text]